In a 19,973-person retrospective cohort of community-dwelling adults ages 40–69 (excluding eGFR <30), CKD stage G3 was linked to a higher risk of incident sleep disorders identified in administrative databases (HR 1.30; 95% CI 1.01–1.65) over a median 11.6 years.

Why It Matters To Your Practice

• Sleep complaints in mild–moderate CKD aren’t just “quality of life” issues — in this cohort, CKD G3 carried a measurable increase in future sleep-disorder diagnoses.

• Sleep disorders also tracked with cardiovascular outcomes, reinforcing sleep as a practical risk signal to capture during routine CKD follow-ups (including in patients with Heart disease).

Clinical Benefits

• Earlier identification: CKD G3 patients may benefit from more consistent sleep screening (insomnia symptoms, OSA risk, restless legs/PLMD, circadian disruption) given higher downstream diagnosis rates.

• Risk stratification: Among CKD G2 patients, a sleep-disorder diagnosis was associated with higher cardiovascular event risk (HR 2.04; 95% CI 1.49–2.79), supporting sleep history as a useful “add-on” risk marker.

Managing Risks

• Don’t over-interpret causality: This was observational and relied on administrative coding for sleep disorders, which can miss subclinical disease and reflect access-to-care patterns.

• Match interventions to CKD realities: Review sedative-hypnotics for renal dosing/accumulation risk, fall risk, and next-day impairment; prioritize nonpharmacologic options (CBT-I, sleep hygiene, OSA evaluation) when feasible.

The Bottom Line

• In mild–moderate CKD, stage G3 was associated with more incident sleep disorders (HR 1.30).

• When CKD patients report sleep problems, treat it as a clinical signal — and consider cardiovascular risk context by eGFR category.